Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Open Access
- 24 May 2019
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (6), 1124-1135
- https://doi.org/10.3324/haematol.2019.218883
Abstract
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients maintained the remission. No significant changes have been registered using different dose schedules and timing of administration, while the combination with other drugs seemed promising. Higher response rates have been observed in young women before the chronic phase, but apart from that, other clinical factors or biomarkers predictive of response are still lacking. In this review we examine the historical and current role of rituximab in the management of primary immune thrombocytopenia, twenty years after its first use for the treatment of autoimmune diseases.Keywords
This publication has 122 references indexed in Scilit:
- B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cellsJCI Insight, 2012
- Immunologic effects of rituximab on the human spleen in immune thrombocytopeniaBlood, 2011
- Efficacy and safety of rituximab in common variable immunodeficiency‐associated immune cytopenias: a retrospective multicentre study on 33 patientsBritish Journal of Haematology, 2011
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agentsBlood, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Repeated courses of rituximab in chronic ITP: Three different regimensAmerican Journal of Hematology, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpuraBlood, 2008
- Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisAnnals of Hematology, 2007
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003